CLINICAL TRIAL: BRAIN DOPAMINE FUNCTION IN ADULTS WITH ADHD

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 本研究的总体目的是调查ADHD成年人大脑DA系统的参与情况，并评估12-14个月治疗期后用兴奋剂哌甲酯长期治疗对大脑DA功能的影响。 目前建议中假设ADHD患者DAT代偿性降低的假设是基于我们在从未接受过药物治疗的ADHD受试者中的初步数据（见第III节）。 我们将遵循在IRB #353中所做的PET扫描研究设计，在IRB #353中，我们成功入组并完成了从未接受过药物治疗的ADHD受试者的研究。 在目前的提案中，PET扫描完成后，ADHD受试者将返回他们的转诊医生进行约12-14个月的慢性治疗期，然后他们将被要求返回进行后续扫描。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall purpose of this study is to investigate the involvement of the brain DA system in adults with ADHD and to assess the effects of chronic treatment with the stimulant drug methylphenidate on brain DA function after a 12-14 month treatment period. The hypothesis in the current proposal that postulates compensatory decreases in DAT in ADHD is based on our pilot data in never-medicated ADHD subjects (see Section III). We will follow the research design for PET scanning as we did in IRB #353 in which we successfully enrolled and completed studies in never medicated ADHD subjects. In the current proposal, after the PET scans are completed, the ADHD subjects will return to their referring physician for a chronic treatment period of about 12-14 months and then they will be asked to return for follow-up scanning.